跳至主要内容
临床试验/NCT05680571
NCT05680571已完成不适用

Validation of Bulbicam for Use on Patient Suffering From Parkinson and Ataxia

Meddoc1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2022年12月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Meddoc
入组人数
64
试验地点
1
主要终点
Saccade

研究概览

简要总结

Aim is to investigate repeatability and stability of four Neurological-related Bulbicam tests in patients suffering Parkinson (PD),Ataxia (AT) and matched healthy control (HC).

Study population The study consists of the patients suffering from PD or AT and HV of both genders above 18 years of age without any eye- or neurological disorder.

Bulbicam will be used in the study and five tests will be performed

The study will be performed as a controlled, open and non-randomized, stratified observational single center. The stratification factors will be pathology (PD&AT) and internal classifications. ed.

The main variables will be the variables recorded at the four Bulbicam tests and the standard neuro-ophthalmological variables included for PD and AT

Participants, who fulfil the inclusion criteria; do not meet any of the exclusion criteria and willing to give informed consent to participate will receive an appointment for starting the study. During the first day of the study, the included patients will undergo a neuro-ophthalmological examination by a neurologist. Additionally, Bulbicam examination will be performed twice with a rest period of one hour between each registration.

The healthy controls will only undergo a standard examination and twice BulbiCam examination. The controls will only participate one day. The patients will participate two more days with two Bulbicam examinations per day.

Sample size:

Sixteen PD-patients ,16 AT-patients and 32 HCs will be included in the study.

详细描述

Aim

  • To investigate repeatability and stability of four Neurological-related Bulbicam tests in patients suffering from PD, AT and HC.
  • To contribute to establishment of normal range for PD and AT patients with different degree in the disease development related to the Bulbicam tests.
  • To contribute to establishment of normal range of these Bulbicam tests for a normal population without neurological or ophthalmological disease.

Study population The study consists of the following three study populations: 1) Patients suffering from PD of both genders above 18 years of age; 2) Patients suffering from AT of both genders above 18 years of age; 3) Gender- and age-matched HC without any eye- or neurological disorder.

Trial equipment Bulbicam will be used in the study and the following five tests will be performed at each investigation: "Fixation", "Saccade" "Nystagmus", "Smooth pursuit" and "Pupil".

Design:

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with either PD or AT of both gender; at least the age of 18 years; without any other eye disease; suffering from other know serious disease but have a health situation in accordance with expectations related to the age.
  • gender- and age-matched controls to patients ; passed the age of 18 years without any eye diseases; not suffering from other know serious disease and have a health situation in accordance with expectations related to the age.

排除标准

  • Other visual disturbances and blindness
  • Posterior Chamber Intraocular Lens (PCIOL)
  • Physical or psychiatric disease, which may disturb the measuring procedure
  • Paresis or paralysis of any oculomotor muscle
  • Patients whose visual acuity is less than 0.1 in any eye, as these will not be able to focus on the test stimuli.
  • Patients whose visible part of the eye is abnormal, such as subconjunctival haemorrhages or deformed pupils
  • Patients whose pupils are not able to respond normally to dilation or contraction due to damaged nerves, mechanical damage of the pupil etc.
  • With known alcoholic and drug dependency
  • Not able to understand information.
  • Not willing to give written consent to participate in the study.

结局指标

主要结局

Saccade

时间窗: 37 hours

Latency in ms

Pupil

时间窗: 37 hours

Diameter in mm

Nystagmus

时间窗: 37 hours

Frequency in Hz

Fixation

时间窗: 37 hours

Stability in mm

Smooth pursuit 1

时间窗: 37 hours

Gain velocity in degree

次要结局

未报告次要终点

研究者

发起方
Meddoc
申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof Stig Larsen

Professor

Meddoc

研究点 (1)

Loading locations...

相似试验

Validation of Bulbicam for Parkinson- and... | 临床试验